Numinus Wellness’ Study On MDMA-Assisted Therapy For PTSD Gets Health Canada Nod

Numinus Wellness Inc. (TSXV: NUMI) announced today that it has secured approval from Health Canada to conduct its feasibility study on MDMA-assisted therapy to treat post-traumatic stress disorder. The health department recently issued a “letter of no objection”, allowing the proposed study to proceed.

The single-arm, open-label safety and feasibility study is sponsored by the Multidisciplinary Association for Psychedelic Studies through its subsidiary MAPS Public Benefit Corporation. 

In May 2021, MAPS reported the results from the Phase 3 clinical trial testing the efficacy and safety of MDMA-assisted therapy for PTSD. The results demonstrated that 88% of the participants that received the experimental sessions experienced clinically significant reduction in symptoms, with 67% no longer qualifying for a PTSD diagnosis compared to only 32% in the placebo group.

Following the federal regulatory approval, the company is gearing its study preparations to train staff, import medication, and obtain ethical approval related to COVID-19 protocols.

Beyond this study, the company is also undertaking further studies to assess the safety and psychoactive properties of the lab-produced extract from a Psilocybe mushroom product.

Numinus Wellness last traded at $1.14 on the TSX Venture.


Information for this briefing was found via Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Numinus Wellness To Acquire Novamind In All Stock Transaction At $0.44 Per Share

Consolidation within the psychedelics space is getting underway, with the announcement this morning that Numinus...

Tuesday, April 12, 2022, 07:56:51 AM

Numinus Wellness To Conduct $10.0 Million Bought Deal

Numinus Wellness (TSXV: NUMI) evidently is seeing strong investor demand, with the psychedelics firm this...

Monday, December 7, 2020, 07:38:26 AM

Numinus Completes First Legal Harvest of Psychedelic Mushrooms

Numinus Wellness (TSXV: NUMI) has become the first publicly issued firm to legally complete a...

Thursday, October 22, 2020, 09:15:00 AM

Numinus Wellness Increases Financing To $15.0 Million

Numinus Wellness (TSXV: NUMI) has increased the size of the bought deal financing that it...

Monday, December 7, 2020, 10:46:35 AM